"2015-12-31+01:00"^^ . . . "0"^^ . . . . . "2015-01-22+01:00"^^ . "2014-03-21+01:00"^^ . "1"^^ . "Dipeptidyl peptidase 4 (DPP-4, identical to CD26) is multifunctional enzyme, participating on a number of immunoregulatory processes. In patients with the diabetes mellitus type 2 treated by DPP-4 inhibitors, changes DPP-4 activity and concentration, concentration of eosinophyllic cationic protein and selected cytokines in blood plasma will be followed. In parallel, proportion of CD26 expressing cells within the CD4 and CD8 cells, together with the relevant enzymatic activity, Treg (CD4+CD25+CD127-/FoxP3+) and CD86+ monocytic cells and alternatively NK cells (presence and activation) and intracellular cytokines in CD4+ IFNgamma/ IL4/ IL17 (Th1/Th2/Th17) supplemented with IL2 and eventually TGFbeta and IL10 will be investigated. The results might help to assess causality of DPP-4 inhibitors' induced immunosupression observed in animals. The results also should help to better define indications of the treatment, namely respective to the autoimmune and oncological comorbidities."@en . "0"^^ . "The impact of DPP-4 inhibitor therapy on immunity functions in patients with type 2 diabetes mellitus"@en . . "1"^^ . "2011-06-01+02:00"^^ . "1"^^ . . . . . . "Dipeptidylpeptid\u00E1za 4 (DPP-4, identick\u00E1 s CD26) je multifunk\u010Dn\u00ED enzym, v\u00FDznamn\u00FD pro \u0159adu imunoregula\u010Dn\u00EDch pochod\u016F. U\u00A0pacient\u016F s diabetem mellitem 2. typu l\u00E9\u010Den\u00FDch inhibitory DPP-4 budou sledov\u00E1ny d\u016Fsledky inhibice tohoto enzymu na\u00A0aktivitu a koncentraci DPP-4, koncentraci eosinofiln\u00EDho katonick\u00E9ho proteinu a vybran\u00FDch cytokin\u016F v krevn\u00ED plasm\u011B. D\u00E1le budou zji\u0161t\u011Bny pom\u011Bry populac\u00ED a exprese CD26 na CD4 a CD8 lymfocytech a jejich DPP-4 aktivita, stanoven\u00ED Treg (CD4+CD25+CD127-/FoxP3+) a CD86+ monocyt\u016F, p\u0159\u00EDpadn\u011B NK (zastoupen\u00ED a aktivace) a kvantifikace intracelul\u00E1rn\u00EDch cytokin\u016F v CD4+ IFNgamma/ IL4/ IL17 (Th1/Th2/Th17) dopln\u011Bn\u00E9 o IL2 a event. TGFbeta a IL10. Vy\u0161et\u0159en\u00ED budou provedena p\u0159ed a po 4 t\u00FDdnech a\u00A012 m\u011Bs\u00EDc\u00EDch l\u00E9\u010Dby DPP-4 inhibitory. V\u00FDsledky umo\u017En\u00ED posoudit vliv inhibice DPP-4 na navozen\u00ED imunosuprese pozorovan\u00E9 u\u00A0experiment\u00E1ln\u00EDch zv\u00ED\u0159at a posoudit jej\u00ED mechanismus. To m\u016F\u017Ee p\u0159isp\u011Bt k racionalizaci indikace s p\u0159ihl\u00E9dnut\u00EDm k p\u0159\u00EDpadn\u00FDm komorbidit\u00E1m, zejm\u00E9na autoimunitn\u00EDm a neoplastick\u00FDm." . . . . . "http://www.isvav.cz/projectDetail.do?rowId=NT12407"^^ . "DPP-4 inhibitors - side effect"@en . . . "Vliv pod\u00E1v\u00E1n\u00ED inhibitor\u016F DPP-4 na imunitn\u00ED funkce u diabetik\u016F 2.typu" . "NT12407" .